The Effectiveness Of Current Hantavirus Vaccines In Clinical Trials
Published on: February 13, 2025
the effectiveness of current hantavirus vaccines in clinical trials featured image
Article author photo

Patrick Chi Ket Toh

BSc Aookued Medical Science, University College London

Article reviewer photo

Malavika Jalaja Prasad

MSc. Nanomedicine, Swansea University, Wales, UK

Introduction

Hantavirus was first discovered during the Korean War, and nearly 30,000 UN troops fell ill with a supposed Korean hemorrhagic fever, later referred to as hemorrhagic fever with renal syndrome (HFRS). The cause was relatively unknown until 1978 when Lee et al. discovered the Hantaan virus (HTNV) which caused the condition. Another virus, Puumala virus (PUUV), can also cause HFRS and was discovered in Finland in the 1980s. Additional viruses that can also cause HFRS include Seoul orthohantavirus (SEOV) and Dobrava-Belgrade orthohantavirus (DOBV). Infections involving hantaviruses gained further attention when, in 1993, there was an outbreak of the disease Hantavirus cardiopulmonary syndrome (HCPS) caused by the Sin Nombre virus (SNV) and Andes virus (ANDV), which was also reported in South America.1

Transmission

These pathogenic viruses causing HFRS and HCPS are largely transmitted by rodents, insectivores, and even bats. The main rodent species carrying the Hantaan virus in Asian populations are Apodemus agrarius and Apodemus peninsulae. Bank voles are the main rodent species carrying the Puumala virus and are mainly present in Europe. In South and North America, the common deer mouse, Peromyscus maniculatus, was the rodent species that spread the Sin Nombre virus and Andes virus.1

Individuals can become infected by inhaling aerosolised virus particles from rodent excretion, such as urine, faeces, and saliva. Infection via rodent bites is rare, but cases have been reported before. The risk of getting infected by Hantaan viruses is related to the closeness of contacts, such as those who have occupations like animal trappers, mammalogists, farmers, and military personnel.1

Epidemiology

HFRS is endemic in China, with most cases occurring on the Asian and European continents. From 2006 to 2012, 77,558 cases were diagnosed, with 866 deaths. So they had an annual incidence rate of 0.83 per 100,000 and a mortality rate of 0.01 per 100,000. While, since the outbreak in 1993, only 34 cases have been confirmed and diagnosed, with more cases being reported in other countries like Uruguay and Panama.2

Hemorrhagic fever with renal syndrome (HFRS)

The clinical manifestations present in HFRS can vary from mild to severe symptoms depending on which viral agent caused the disease. The phase of HFRS is divided into five phases: febrile, hypotensive, oliguric, polyuric, and convalescent (recovery). 

There’s an incubation period that lasts between 2 and 4 weeks, during which the individual infected with HTNV is asymptomatic. After the incubation period, they begin presenting with a high fever, chills, headache, backache, and petechiae, round spots forming on the skin that look like rashes. Next is the febrile phase, which usually lasts up to 3 to 7 days. The symptoms manifested are usually high-grade fever and by the end of the phase, conjunctival haemorrhage, where a blood vessel breaks within the eye, causing a haemorrhage, and fine petechiae begin to form on the roof of the mouth. 

The third stage, called the hypotensive stage can last between several hours and 2 days. During this stage, blood pressure drops, and in severe cases, shock may occur, causing one-third of HFRS deaths. Further characteristic symptoms are present, like thrombocytopenia (low blood platelet count) and leukocytosis (an increase in white blood cell count).

This is also the stage where hemorrhagic manifestations become more apparent, including petechiae on the skin and mucosa, haematuria, fatal intracranial haemorrhage of the brain, and epistaxis (internal bleeding within the nose).

The next stage, the oliguric phase can last from 3 to 7 days. In this phase, the blood pressure becomes normalised, but kidney function worsens, leading to oliguria or even anuria, low urine output, proteinuria, atypical sediments forming in the urine, including microscopic haematuria, and azotaemia (a high amount of waste products like urea are present in the blood). These symptoms can also be accompanied by abdominal or back pain. The polyuric phase is where renal function recovers and urinary output starts to increase again.1

Hantavirus cardiopulmonary syndrome (HCPS)

The HCPS is a more severe condition with a fatality rate of 30–50%. HCPS has three phases: prodromal, cardiopulmonary, and convalescent. Clinical manifestations can range from mild hypoxaemia to respiratory failure with cardiogenic shock. 

The prodromal phase begins with symptoms similar to the flu, such as high fever, chills, myalgia, nausea, headache, etc. Then, affected individuals rapidly progress to the cardiopulmonary phase with abrupt onset to progressive cough, shortness of breath, and tachycardia. Soon, individuals begin to develop acute non-cardiac pulmonary oedema and hypotension. Moreover, pleural effusion starts to develop bilaterally, infiltrating the lungs, causing respiratory failure, and requiring mechanical ventilation. If an individual case is severe, it can be complicated by cardiogenic shock, lactic acidosis, and massivehaemoconcentration—an increase in red blood cell count and a reduction in plasma volume. Finally, during the convalescent phase, patients begin to recover but complain about weakness, fatigue, and impaired tolerance to exercise.1

Types of hantavirus vaccines in clinical trials

Vaccines are important for the prevention of the spread of Hantavirus. Currently, there are quite a few approved Hantavirus vaccines in Asia, but no vaccines have been approved in the western part of the world, which will be discussed down below.

Inactivated vaccine

Inactivated vaccines are vaccines that consist of the entire structure of a virus that has been inactivated via heat or chemicals. The first successful commercial Hantavirus vaccine to protect from HFRS was produced in Korea called Hantavax in 1990. The number of cases fell from 1234 to 415 between 1991 and 1997. Furthermore, a phase III trial (2016) looked at the effectiveness of Hantavax with three doses, they discovered the first dose gave a seroconversion rate of 90.41%—seroconversion rate means how many specific antibodies can be produced. However, they also found that after having two doses, patients had a fall off of 23.24%. Additionally, the Korean military from 2011 to 2017 found they only had an effectiveness of 59.1%, but its effectiveness in areas with a high incidence of hantavirus cases was more significant (2018).2

China developed its vaccine in 1994, a bivalent inactivated vaccine which was approved in 2005. The vaccine had quite a big impact, significantly reducing the number of cases to only 20,000 per year. Li et al. (2017) evaluated the vaccine’s effectiveness and found it had a positive level of neutralising antibodies in treated individuals, and those vaccinated could sustain humoral immunity for up to 33 months.2,3

DNA vaccines

DNA vaccines specifically target the M gene segment of the hantavirus, its main role is to develop the membrane glycoprotein of hantaviruses. Hooper et al. (2001) developed a variety of DNA vaccines with the M gene encoded, testing them with hamsters, they found the HTNV M gene had protective effects against HTNV, SEOV, and DOBV in hamsters, also inducing high levels of neutralising antibodies in rhesus monkeys. Another DNA vaccine was constructed this time containing a plasmid of a full-length M genome fragment of ANDV, when inoculated into Rhesus monkeys, they had high levels of neutralising antibodies and other hantavirus strains (2003).4

Furthermore, M-gene DNA vaccines could provide immunity to PUUV but not to DOBV infections. Finally, another vaccine using SNV DNA was developed, and when given to rabbits, it could increase their neutralising antibodies. Moreover, when hamsters were vaccinated three times with the vaccine, and became infection-free from SNV (2013).2

Subunit vaccines

Subunit vaccines are different from inactivated vaccines in that they only have certain components of a virus rather than the whole version. They are easy to produce and don’t easily interfere with other components, making it easier to create multivalent vaccines like the MMR vaccine.

Research has found the importance of nucleocapsid protein in the development of vaccines, as it is found in all the different types of hantaviruses. Recombinant nucleocapsid proteins (rN) from PUUV, ANDV, and DOBV have been found to induce cross-protective immunity to PUUV, with ANDV rNs producing the most reactivity to PUUV antigens (2002). Furthermore, Schmidt et al, (2005) have reported that nucleocapsid proteins of SEOV can react with SEOV monoclonal antibodies and some reactivity with PUUV- and HTNV monoclonal antibodies, showing recombinant vaccines have some versatility against several hantaviruses.2,5

Current challenges

The requirement for the use of vaccines is based on the likelihood of individuals being close to rodents infected with hantaviruses. Despite the large vaccination program in China, they still have the largest number of HFRS cases and deaths. HFRS is also widespread in Europe, PUUV benign is the main cause of cases, but DOBV-associated HFRS is more common. However, vaccine development in Europe is highly dependent on the commercial industry, where the marketability of HFRS vaccines is highly underappreciated. Additionally, HPS is a rare disease, and cases are infrequent and sporadic, so the cost-to-benefit ratio is disadvantageous to developing HCPS vaccines.6

Summary

Hantavirus is a virus that can cause two types of conditions: hemorrhagic fever with renal syndrome (HFRS) and Hantavirus cardiopulmonary syndrome (HCPS). Many vaccines have been developed, but few have been approved. Korea and China have managed to develop and approve vaccines with good effects. Currently, in Europe and the US, various vaccines with hantavirus have been developed—subunit, inactivated, DNA, and recombinant, but none have been fully approved. These vaccines have shown protective immunity against hantaviruses, however, immunity can be short. Additionally, hantavirus cases are sporadic, with no marketability, and so there’s a lack of approved and developed vaccines in Europe and America.

References

  1. Avšič-Županc T, Saksida A, Korva M. Hantavirus infections. Clinical Microbiology and Infection [Internet]. 2019 Apr 1 [cited 2024 Sep 19];21:e6–16. Available from: https://www.sciencedirect.com/science/article/pii/S1198743X15005364
  2. Liu R, Ma H, Shu J, Zhang Q, Han M, Liu Z, et al. Vaccines and therapeutics against hantaviruses. Front Microbiol [Internet]. 2020 Jan 30 [cited 2024 Sep 19];10. Available from: https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2019.02989/full
  3. Li Z, Zeng H, Wang Y, Zhang Y, Cheng L, Zhang F, et al. The assessment of Hantaan virus-specific antibody responses after the immunization program for hemorrhagic fever with renal syndrome in northwest China. Hum Vaccin Immunother [Internet]. 2016 [cited 2025 Feb 6]; 13(4):802–7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404621/.
  4. Hooper JW, Moon JE, Paolino KM, Newcomer R, McLain DE, Josleyn M, et al. A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for haemorrhagic fever with renal syndrome delivered by intramuscular electroporation. Clin Microbiol Infect. 2014; 20 Suppl 5:110–7. Available from: https://pubmed.ncbi.nlm.nih.gov/24447183/
  5. Schmidt J, Jandrig B, Klempa B, Yoshimatsu K, Arikawa J, Meisel H, et al. Nucleocapsid protein of cell culture-adapted Seoul virus strain 80-39: analysis of its encoding sequence, expression in yeast and immuno-reactivity. Virus Genes. 2005; 30(1):37–48. Available from: https://pubmed.ncbi.nlm.nih.gov/15744561/
  6. Schmaljohn CS. Vaccines for hantaviruses: progress and issues. Expert Review of Vaccines [Internet]. 2012 May [cited 2024 Sep 19];11(5):511–3. Available from: http://www.tandfonline.com/doi/full/10.1586/erv.12.15
Share

Patrick Chi Ket Toh

BSc Aookued Medical Science, University College London

I'm an undergraduate in my second year studying BSc Aookued Medical Science at UCL with a passion for science writing. My specific scientific interests are immunology and nutrition. I am currently the marketing officer, social secretary and writer for one of the university life science magazines responsible for society's social media and planning out social events.

arrow-right